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Selectively switching on europium emission in drug site one of 
human serum albumin  
Sergey Shuvaev, Robert Pal and David Parker *
A luminescent europium probe has been discovered that binds 
selectively to drug-site I in human serum albumin, signalled by a 
‘switching on’ of europium emission, and accompanied by strong 
induced circularly polarised luminescence.        
Albumin is the most abundant serum protein in mammals, and 
plays a key role in the transport both of endogenous 
compounds, such as fatty acids (FA) and hormones, and a wide 
range of drugs where it regulates their pharmacokinetics and 
bioavailability. 1,2 Detailed structural and computational 
studies have revealed its structural plasticity, with seven 
binding pockets present that explain its ability to bind many 
different types and sizes of compound.3-5  The two main drug 
binding sites in human serum albumin (HSA) are termed 
Sudlow's drug site I and II, (DS-1, DS-2), and are distinguished 
by the fact that DS-1 binds predominantly by a solvophobic 
interaction, whereas DS-2 binding has been rationalised in 
terms of combined electrostatic, directed hydrogen-bonding 
and hydrophobic binding contributions, notably for anionic 
guests.  The prototypical drugs that bind selectively to each of 
these sites in HSA are ibuprofen (DS-2; log K 6.4) and 
iodipamide (DS-1, log K = 7.0, 298 K, I = 0.1 M NaCl).  These 
drugs bind with lower affinity to some of the other protein 
binding sites. 1   
 
There are significant structural differences in the albumins of 
different animal species.  Bovine serum albumin (BSA), for 
example, has only 76% structural homology with HSA and the 
DS1 pocket is much more exposed to water, partly explaining 
the different affinity profile for a given drug or metabolite.6 It 
also possesses an additional aromatic amino-acid residue, Trp-
134, that it located in one of the weaker binding pockets, (FA-
1).  The importance of the serum albumins has triggered 
studies of their direct detection in serum or in urine, using 
various luminescent probes.7-9 The presence of HSA in urine 
signals the onset of renal malfunction, whilst a deficiency in 
blood is associated with liver disease, e.g. cirrhosis and chronic 
hepatitis.  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 We and others have been studying a range of long-lived 
lanthanide(III) probes, suitable for use in detecting changes in 
pH and pX (e.g. X = urate, citrate, lactate, bicarbonate) both in 
vitro and in living cells,10-14 using spectral imaging in 
fluorescent confocal microscopy.15 During the course of these 
studies, we evaluated the medium and pH-dependence of 
emission from the Eu(III) complexes, [Eu.L1] and [Eu.L2].  Aware 
of the ability of the conjugated chromophore to exhibit 
solvatochromism, 16,17 wherein the energy of the 
intramolecular charge transfer transition varies sensitively with 
solvent polarity, we have also examined their emissive 
behaviour in the presence of both BSA and HSA.  Furthermore, 
this study has been extended to embrace live cell-imaging 
studies, changing the foetal calf-serum (containing BSA) in the 
cell-growth medium to goat and human serum, to assess the 
effect on emission and cell uptake. 
Each of the ligands, L1 and L2, was prepared from trans-1,7-
bis(tert-butoxy-carbonylmethyl)-1,4,7,10 
tetraazacyclododecane by stepwise alkylation reactions (ESI).  
The europium(III) complexes were purified by reverse-phase 
HPLC and exhibited significantly different photophysical 
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behaviour in solution, in accord with the sensitivity of the 
energy of the ICT excited state of [Eu.L1] to its local 
environment, (Table 1).  The absorption spectrum of [Eu.L1] in 
water showed a very broad absorption band at 365 nm, but 
gave rise to no europium emission over the pH range 3 to 8.  
As the solvent polarity was reduced, the europium emission 
was 'switched on', being strongest in the least polar solvents, 
THF and 1,4-dioxane, (Figure 1).  
                             
Figure 1   Variation of europium total emission with Reichardt’s 
normalised solvent polarity parameter.  
 
 Moreover, incremental addition of HSA, to a solution of 
[Eu.L1] in phosphate-buffered saline (pH 7.4, 295 K) also led to 
a 'switching-on' of europium luminescence, (Figure 2) 
accompanied by a strong induced circularly polarised 
luminescence (CPL) signal, with gem (589 nm) = –0.2.  The 
emission intensity of the protein-bound complex was pH 
dependent, (Figure 2), with an apparent pKa of 7.22(±0.01), 
associated with reversible, intramolecular sulfonamide 
ligation.  The form of the protein binding curve and the 
extended range of the sensitivity to added protein suggested 
binding of the complex may occur to more than one protein 
site.  In the presence of a 100-fold excess of added HSA, the 
lifetime of europium emission was 0.3 ms, the intensity was 
insensitive to degassing the solution and the excitation 
spectrum showed a band at 390 nm, likely to be an internal 
charge transfer band.  A significant bathochromic shift of this 
excitation band, when compared to the absorption spectrum 
of [Eu.L1] without serum albumin and its excitation spectra in 
different solvents (Figure 1) suggest the presence of 
intermolecular stacking interactions between alkynylpyridine 
moieties. Under the same conditions using added BSA, the 
lifetime of the observed emission was 0.18 ms, and the overall 
emission intensity was fifteen times lower,   (Table 1).  
The emission behaviour is consistent with binding of the 
complex into a hydrophobic HSA site, e.g. DS1, that leads to a 
tightening of the ICT excited state manifold, and a more 
efficient overall europium sensitisation pathway.  Accordingly, 
iodipamide – a drug that binds most strongly to DS-1, 3 was 
added incrementally to a solution containing [Eu.L1] (30 µM) 
and HSA (9 µM).  The intensity dropped by a factor of five, and 
residual Eu luminescence was observed, even with a large 
excess of added iodipamide, suggesting that [Eu.L1] was also 
bound to other hydrophobic binding sites on the protein. 
Competitive displacement of [Eu.L1] from DS-1 by iodipamide 
is occurring, (Figure 3), with an apparent affinity constant for 
[Eu.L1] binding of log K = 5.29(06) M–1, in reasonable 
agreement with the global value of 6.00, obtained by 
monitoring the ‘switching on’ of Eu emission by adding the 
free Eu complex to HSA (Figure 2). A parallel competitive 
binding experiment was undertaken with added ibuprofen, to 
probe affinity for drug-site II, (DS-2), (Figure 3). In this case, a 
two-step displacement curve was obtained, with a much 
smaller reduction of 50% in total emission intensity, suggesting 
that [Eu.L1] binds to DS-1 and DS-2 at least, with an overall site 
affinity that is of the order of 3 x 105 M–1.  
 
        
     
Figure 2   (upper): variation of Eu emission intensity as [Eu.L1] is 
added to HSA (295K, 0.1 M NaCl, 11 M protein; log K = 6.00 (02); 
the inset shows the induced CPL spectrum recorded for the protein 
bound complex; (lower): the pH dependence of Eu emission in the 
human serum albumin bound complex (295K, 0.1 M NaCl, 10 M 
[Eu.L1]) fitted as a Boltzman sigmoid. 
 
The affinity of the lanthanide(III) complex with BSA and HSA 
was also examined in a parallel study of the protein 
dependence of relaxivity changes with [Gd.L1].18  Incremental 
addition of protein (BSA or HSA) to [Gd.L1] (1.2 mM, 310 K, 1.4 
T) led to a 4-fold increase in the water proton relaxation rate 
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with HSA, compared to a 2.6 fold increase with BSA, (ESI). The 
similarity in the form of the binding curves suggested 
approximately equal overall protein affinities, with log K values 
of the order of 3.5 (0.2), (ESI). The pH dependence of the 
HSA/[GdL1] adduct revealed enhanced relaxivity at lower pH, 
as the sulphonamide nitrogen atom dissociated, with a pKa 
value of 6.36(06) in agreement with related protein-bound 
systems. 19 Addition of iodipamide or ibuprofen to each of the 
HSA-bound Gd complexes did not change the measured 
relaxivity by more than 10%, suggesting that the Gd complex 
also binds to protein binding pockets with moderate affinity 
that do not accommodate either of these drugs. The overall 
enhanced relaxivity value measured is caused by modulation 
of the rotational correlation time (τc) of the Gd complex and 
reflects the weighted contributions of the bound complex in 
the different binding sites. 19    
 
Table 1.   Selected photophysical properties of [Eu.L1] and [Eu.L2] 
(295 K, H2O) 
Complex [Eu.L1] [Eu.L2] 
abs/nm 365 325 
(H2O) 28,000 35,400 
H2O
/ms    c 0.73 (pH 6) 
D2O
/ms    c 1.00 (pH 6) 
H2O
 + HSA/msa 0.30 
0.18 
0.79 
1.02 
Eu/% 0 6.6 
Eu + HSA/%
a 0.7 6.0 (4.3)b 
       a Added protein concentration was 0.7 mM;  b value in 
parenthesis is for added BSA; c   No measurable emission in solution. 
 
The emission behaviour of [Eu.L2] was completely different to 
[Eu.L1].  Excitation into the primary absorption band at 325 nm 
led to long-lived europium emission that was not significantly 
changed in form or intensity in the presence of added HSA or 
BSA.  The protein bound complex gave rise to a weak induced 
CPL signal, with gem (589 nm) = –0.02.  However, the form of 
the CPL spectrum was identical to that observed with [Eu.L1] 
suggesting a common local chiral protein environment, i.e. a 
common binding pocket in which Eu CPL can be observed.   In 
saline solution, the pH-dependence of Eu emission was 
monitored; the spectral form, the emission intensity, and the 
lifetime increased with pH.  An apparent pKa value of 3.80(06) 
was estimated (ESI) associated with reversible binding of the 
sulfonamide nitrogen atom to the Eu ion.  This pKa value 
increased to 6.8 in a cell lysate medium. 20 In comparison, 
[Eu.L1] when bound to excess HSA also exhibited a pH-
dependent emission response, with an apparent pKa around 
7.22(05) (ESI).  It had earlier been noted that in a hydrophobic 
binding pocket, e.g. DS-1, an apparent pKa may rise by up to 3 
units versus bulk solution, i.e. the protonation equilibrium is 
significantly perturbed by protein association. 21    
Each Eu(III) complex was examined as a luminescent cellular 
stain in living mouse fibroblast cells (NIH-3T3) using both live 
cell epi and confocal microscopy.  In the incubation medium, 
10% foetal calf-serum (FCS) is normally added to promote cell 
growth; FCS contains BSA.  Accordingly, different cell growth 
media were created to replace FCS based on added heat 
inactivated purified culture grade human or goat serum.  In the 
cell medium, the Eu emission could only be easily discerned by 
spectral imaging for the HSA-added preparation.  Following an 
incubation of 4h in respective growth medium containing up to 
100 µM [Eu.L1] and keeping all experimental parameters 
constant, the Eu staining was 50% brighter for the HS-medium 
vs FCS-medium.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Variation of europium emission intensity in the presence of 
HSA showing the fit (line) to the data points: (upper): with 
added iodipamide ([Eu.L1] 30 M; [HSA] 9.0 M), log K = 
5.29(03); (lower): with added ibuprofen ([Eu.L1] 26 M; [HSA] 
9.4 M, log K = 5.16(03), fitted assuming a 1:1 binding 
isotherm). Note that the y axis in the lower case, denotes 
I(final)/I , at 612 nm, showing the 50% change.  
 
A lysosomal staining pattern was confirmed by co-staining with 
LysoTracker GreenTM (P >0.83, ESI and Figure 4).  The 
brightness of cell images was promoted to 120% increase vs 
FCS medium when the local lysosomal pH (normally around 
4.2-4.5) was adjusted to 6.5, following addition of nigericin (5 
min, 200 nM)10a. This study allowed consideration of the 
question as to whether it is enhanced intracellular uptake in 
the presence of HSA or enhanced complex brightness in cellulo 
that explains the variation of Eu emission intensity observed 
by microscopy. Independent measurement of the total Eu 
intracellular concentration for each incubation, was 
determined by ICP-MS measurements.  No significant 
differences in Eu concentrations were observed between 
incubations of [Eu.L1] with added HSA and BSA (62% and 60% 
accumulation, respectively).  However, the sample incubated 
with GSA showed a much lower intracellular concentration 
(29%). At the same time, [Eu.L2] incubated with added HSA 
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showed similar cellular uptake (55%), hinting that the 
mechanism of cellular uptake of [Eu.L1] and [Eu.L2] may be 
similar in nature.   
 
 
Figure 4   LSCM images (1024x1024 pixel, 100Hz bidirectional) in 
NIH-3T3 cells showing:  (upper) predominantly lysosomal staining 
following a 4h incubation of 20µM complex (λex = 355 nm, λem = 605-
720 nm, 8 mW),  and 5 min incubation of LTG (λex = 488 nm, λem = 
500-530 nm, 2 mW),    (ambient lysosomal pH is ca. 4.5); 
(centre/lower): enhanced image intensity following a 5 min 
incubation with nigericin (200 nM) and LysoTracker Green (central 
columns), RGB merge highlighting correspondence (scale bar 20 
µM). 
 
In summary, the luminescence of the europium complex, 
[Eu.L1] is switched on when bound to HSA but not to BSA or 
GSA. The europium complex prefers to bind to drug-site one 
and with relatively high affinity, suggesting potential uses in 
drug screening assays that probe the HSA protein site 
selectively. These observations have been extended to cell 
imaging studies.  By replacing BSA (e.g. as calf serum) by HSA 
in the cell-growth medium, much more intense probe emission 
in the lysosomes could be observed, especially at the elevated 
pH values that are known to characterise the presence of 
lysosomal storage diseases.   
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